IVIG (Intravenous Immunoglobulin)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Development History

Sep '26

ARGXPhase 3$58.8B

✓Completed

IVIG (Intravenous Immunoglobulin) Phase 3 Est. Readout

IVIG (Intravenous Immunoglobulin)• Multifocal Motor Neuropathy (MMN)154

Sep 2026~Confirmed

Competitive Landscape

0 competitors in Multifocal Motor Neuropathy (MMN)

Drug Information

Target Indication

Multifocal Motor Neuropathy (MMN)

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ARGX

argenx SE

Related Pipeline

Pemphigus Vulgaris

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Active Idiopathic Inflammatory Myopathy

Postural Orthostatic Tachycardia Syndrome

Generalized Myasthenia Gravis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts